TY - JOUR
T1 - Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants
AU - Arizti-Sanz, Jon
AU - Bradley, A’Doriann D.
AU - Zhang, Yibin B.
AU - Boehm, Chloe K.
AU - Freije, Catherine A.
AU - Grunberg, Michelle E.
AU - Kosoko-Thoroddsen, Tinna Solveig F.
AU - Welch, Nicole L.
AU - Pillai, Priya P.
AU - Mantena, Sreekar
AU - Kim, Gaeun
AU - Uwanibe, Jessica N.
AU - John, Oluwagboadurami G.
AU - Eromon, Philomena E.
AU - Kocher, Gregory
AU - Gross, Robin
AU - Lee, Justin S.
AU - Hensley, Lisa E.
AU - MacInnis, Bronwyn L.
AU - Johnson, Jeremy
AU - Springer, Michael
AU - Happi, Christian T.
AU - Sabeti, Pardis C.
AU - Myhrvold, Cameron
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/8
Y1 - 2022/8
N2 - The widespread transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for rapid nucleic acid diagnostics that are easy to use outside of centralized clinical laboratories. Here we report the development and performance benchmarking of Cas13-based nucleic acid assays leveraging lyophilised reagents and fast sample inactivation at ambient temperature. The assays, which we named SHINEv.2 (for ‘streamlined highlighting of infections to navigate epidemics, version 2’), simplify the previously reported RNA-extraction-free SHINEv.1 technology by eliminating heating steps and the need for cold storage of the reagents. SHINEv.2 detected SARS-CoV-2 in nasopharyngeal samples with 90.5% sensitivity and 100% specificity (benchmarked against the reverse transcription quantitative polymerase chain reaction) in less than 90 min, using lateral-flow technology and incubation in a heat block at 37 °C. SHINEv.2 also allows for the visual discrimination of the Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants, and can be run without performance losses by using body heat. Accurate, easy-to-use and equipment-free nucleic acid assays could facilitate wider testing for SARS-CoV-2 and other pathogens in point-of-care and at-home settings.
AB - The widespread transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for rapid nucleic acid diagnostics that are easy to use outside of centralized clinical laboratories. Here we report the development and performance benchmarking of Cas13-based nucleic acid assays leveraging lyophilised reagents and fast sample inactivation at ambient temperature. The assays, which we named SHINEv.2 (for ‘streamlined highlighting of infections to navigate epidemics, version 2’), simplify the previously reported RNA-extraction-free SHINEv.1 technology by eliminating heating steps and the need for cold storage of the reagents. SHINEv.2 detected SARS-CoV-2 in nasopharyngeal samples with 90.5% sensitivity and 100% specificity (benchmarked against the reverse transcription quantitative polymerase chain reaction) in less than 90 min, using lateral-flow technology and incubation in a heat block at 37 °C. SHINEv.2 also allows for the visual discrimination of the Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants, and can be run without performance losses by using body heat. Accurate, easy-to-use and equipment-free nucleic acid assays could facilitate wider testing for SARS-CoV-2 and other pathogens in point-of-care and at-home settings.
UR - http://www.scopus.com/inward/record.url?scp=85131086778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131086778&partnerID=8YFLogxK
U2 - 10.1038/s41551-022-00889-z
DO - 10.1038/s41551-022-00889-z
M3 - Article
C2 - 35637389
AN - SCOPUS:85131086778
SN - 2157-846X
VL - 6
SP - 932
EP - 943
JO - Nature Biomedical Engineering
JF - Nature Biomedical Engineering
IS - 8
ER -